他汀类药物使用与非霍奇金淋巴瘤及慢性淋巴细胞白血病患者生存的相关性
该研究基于瑞典淋巴瘤和癌症登记处2007至2013年确诊的16 098例非霍奇金淋巴瘤(NHL)和慢性淋巴细胞白血病(CLL)患者,评估诊断前后他汀使用与淋巴瘤特异性、心血管及全因死亡的关系。
要点
- 他汀使用与NHL总体及各亚型的淋巴瘤特异性死亡无一致关联。
- CLL患者他汀使用与全因和心血管死亡相关,但与淋巴瘤特异性死亡关联不一致。
核心结论
- 他汀使用与淋巴瘤生存改善无关,但在淋巴瘤治疗期间使用似乎是安全的。
研究设计与样本
- 基于瑞典淋巴瘤和癌症登记处的回顾性队列研究,纳入2007至2013年确诊的16 098例NHL和CLL患者。
- 采用Cox回归估计诊断前后他汀使用(是/否、强度)与淋巴瘤特异性、心血管及全因死亡的HR和95%CI。
主要发现
- 20%的患者在诊断时使用他汀。
- 诊断前后他汀使用及他汀强度与NHL总体或任何亚型的任何死亡结局均无一致关联。
- 在CLL患者中,他汀使用与全因和心血管死亡相关,但与淋巴瘤特异性死亡的关联不一致。
临床怎么用
- 淋巴瘤治疗期间使用他汀未显示增加淋巴瘤特异性死亡风险,可考虑继续使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Statin use has been associated with reduced mortality from several cancers but also suggested, in vitro, to diminish the effectiveness of lymphoma treatments including rituximab. The present study aimed to assess the association of statin use with mortality in patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia (CLL). We identified all incident NHLs and CLLs in Sweden from 2007 to 2013 with subtype information in the Swedish Lymphoma and Cancer Registers. Using Cox regression, we estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for the association of pre- or post-diagnosis statin use (yes/no, intensity) with lymphoma-specific, cardiovascular, or all-cause mortality; and for follicular lymphoma (FL) by initial treatment strategy (active/watch-and-wait). Among 16 098 incident NHL/CLL patients, 20% used statins at diagnosis. Pre- and post-diagnosis statin use, and statin intensity were not consistently associated with any mortality outcome in patients with NHL, overall or for any subtype. For actively treated patients with FL, statin use did not appear to increase lymphoma-specific mortality (vs. non-users, HR [95% CI]after diagnosis 0·87 [0·45-1·67]). For CLL, statin use was associated with all-cause and cardiovascular but not consistently with lymphoma-specific mortality. In conclusion, statin use was not associated with improved lymphoma survival but appears safe to use during lymphoma treatment.
引用
- Brånvall E, Ekberg S, Eloranta S, et al. Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era. Br J Haematol. 2021. PMID: 34331461. doi:10.1111/bjh.17733
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。